Patent application number | Description | Published |
20120077202 | Expression of FABP4 and Other Genes Associated with Bladder Cancer Progression - Disclosed are methods for predicting the risk of bladder cancer progression, including death from bladder cancer by determining gene expression levels of FABP4 and MBNL2 or other markers where increased levels correlate with lack of progression of the subject's bladder cancer, and decreased levels correlate with progression or death from bladder cancer, and/or determining gene expression levels of COL4A1, UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and/or CDC25B or other markers where increased levels correlate with progression of the subject's bladder cancer or death from it, and decreased levels correlate with lack of progression of bladder cancer. | 03-29-2012 |
20120077703 | Expression of MBNL2 and Other Genes Associated with Bladder Cancer Progression - Disclosed are methods for predicting the risk of bladder cancer progression, including death from bladder cancer by determining gene expression levels of FABP4 and MBNL2 or other markers where increased levels correlate with lack of progression of the subject's bladder cancer, and decreased levels correlate with progression or death from bladder cancer, and/or determining gene expression levels of COL4A1, UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and/or CDC25B or other markers where increased levels correlate with progression of the subject's bladder cancer or death from it, and decreased levels correlate with lack of progression of bladder cancer. | 03-29-2012 |
20120082994 | Expression Levels of COL4A1 and other Markers Correlating with Progression or Non-Progression of Bladder Cancer - Disclosed is determining expression levels protective or harmful markers for bladder cancer prognosis; particularly, determining the expression levels of COL4A3BP alone or in combination with the expression levels of MBNL2, FABP4, and NEK1 or other markers where increased expression levels of these protective markers relative to a control correlates with lack of bladder cancer progression and decreased expression levels correlates with bladder cancer progression or death. Also disclosed is determining the expression levels of COL4A1 alone or in any combination with the expression levels of UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and CDC25B or other markers where increased expression levels of these harmful markers relative to a control correlates with bladder cancer progression or death and decreased expression levels correlates with lack of bladder cancer progression Also disclosed are signatures of protective and harmful markers to predict likelihood of bladder cancer progression or non-progression. | 04-05-2012 |
20120083424 | Expression of UBE2C and Other Genes Associated with Bladder Cancer Progression - Disclosed are methods for predicting the risk of bladder cancer progression, including death from bladder cancer by determining gene expression levels of FABP4 and MBNL2 or other markers where increased levels correlate with lack of progression of the subject's bladder cancer, and decreased levels correlate with progression or death from bladder cancer, and/or determining gene expression levels of COL4A1, UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and/or CDC25B or other markers where increased levels correlate with progression of the subject's bladder cancer or death from it, and decreased levels correlate with lack of progression of bladder cancer. | 04-05-2012 |
20130122504 | Expression Levels of COL4A3BP and other Markers Correlating with Progression or Non-Progression of Bladder Cancer - Disclosed is determining expression levels of protective or harmful markers for bladder cancer prognosis; particularly, determining the expression level of COL4A3BP alone or in combination with expression levels of MBNL2, FABP4, and NEK1 or other markers where increased expression levels of these protective markers relative to a control correlates with lack of bladder cancer progression and decreased expression levels correlate with bladder cancer progression or death. Also disclosed particularly is determining the expression level of COL4A1 alone or in combination with expression levels of UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and CDC25B or other markers where increased expression levels of these harmful markers relative to a control correlates with bladder cancer progression or death and decreased expression levels correlate with lack of bladder cancer progression. Also disclosed are signatures of protective and harmful markers to predict likelihood of bladder cancer progression or non-progression. | 05-16-2013 |
20140249041 | Marker of Prostate Cancer - An SLC18A2 gene serves as a marker of prostate cancer. Methods are provided for diagnosing prostate cancer, predicting or prognosticating the disease outcome, predicting recurrence following surgery, and monitoring disease progression in an individual having prostate cancer. The methods relate to determining the methylation state of an SLC18A2 gene and/or determining the level of transcription or translation of the gene in a sample from the individual. Methods of treating prostate cancer are also provided. The invention also pertains to compositions and kits for use in the methods. | 09-04-2014 |
Patent application number | Description | Published |
20100303795 | MARKER OF PROSTATE CANCER - An SLC18A2 gene serves as a marker of prostate cancer. Methods are provided for diagnosing prostate cancer, predicting or prognosticating the disease outcome, predicting recurrence following surgery, and monitoring disease progression in an individual having prostate cancer. The methods relate to determining the methylation state of an SLC18A2 gene and/or determining the level of transcription or translation of the gene in a sample from the individual. Methods of treating prostate cancer are also provided. The invention also pertains to compositions and kits for use in the methods. | 12-02-2010 |
20120115750 | Expression of FABP4 and Other Genes Associated with Bladder Cancer Progression - Disclosed are methods for predicting the risk of bladder cancer progression, including death from bladder cancer by determining gene expression levels of FABP4 and MBNL2 or other markers where increased levels correlate with lack of progression of the subject's bladder cancer, and decreased levels correlate with progression or death from bladder cancer, and/or determining gene expression levels of COL4AI, UBE2C, BIRC5, COLI8A1, KPNA2, MSN, ACTA2, and/or CDC25B or other markers where increased levels correlate with progression of the subject's bladder cancer or death from it, and decreased levels correlate with lack of progression of bladder cancer. | 05-10-2012 |
20120122722 | Expression of MBNL2 and Other Genes Associated with Bladder Cancer Progression - Disclosed are methods for predicting the risk of bladder cancer progression, including death from bladder cancer by determining gene expression levels of FABP4 and MBNL2 or other markers where increased levels correlate with lack of progression of the subject's bladder cancer, and decreased levels correlate with progression or death from bladder cancer, and/or determining gene expression levels of COL4A1, UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and/or CDC25B or other markers where increased levels correlate with progression of the subject's bladder cancer or death from it, and decreased levels correlate with lack of progression of bladder cancer. | 05-17-2012 |
20130183345 | Treatment of Bladder Cancer Following Detection of Expression Levels of Certain Progression Markers - Disclosed is determining expression levels of protective or harmful markers for bladder cancer prognosis and treatment; particularly, determining the expression levels of protective markers (COL4A3BP, MBNL2, FABP4, NEK1 and SKAP2) and harmful markers (COL4A1, UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and CDC25B) and making treatment decisions in consideration of increased or decreased risk of progression based on the marker expression levels. | 07-18-2013 |
Patent application number | Description | Published |
20080317276 | HIGH EFFICIENT MINIATURE ELECTRO-ACOUSTIC TRANSDUCER WITH REDUCED DIMENSIONS - The present invention relates to a miniature electro-acoustic transducer including a magnetic circuit, a diaphragm and a voice coil operatively connected to the diaphragm. The magnetic circuit includes first and second air gap portions adapted to receive first and second voice coil segments, respectively. The magnetic flux acting on the first voice coil segment is provided by inner magnetic means and first outer magnetic means in combination and the magnetic flux acting on the second voice coil segment is essentially provided by the inner magnetic means only. | 12-25-2008 |
20090000426 | Razor Blade Cleaning and Sharpening Device - The present invention relates to a device and a method for sharpening and cleaning a safety razor blade. The device comprises a polymer-based mat and either one or more polymer-based holding elements ( | 01-01-2009 |
20090003645 | Miniature Voice Coil With Integrated Coupling Coil - The present invention relates to a miniature electro-acoustic transducer comprising a voice coil comprising an air gap voice coil portion at least partly positioned in an air gap of a magnet assembly, and a second voice coil portion attached to a diaphragm of the miniature transducer. The thickness of the second voice coil portion is 2-5 times larger than the thickness of the first voice coil portion. Moreover, the present invention relates to a voice coil for use in a miniature electro-acoustic transducer | 01-01-2009 |
20110064260 | INSERT MOLDED SUSPENSION MEMBER WITH MECHANICAL SUPPORT - A suspension member for a diaphragm, the suspension member comprising a first portion being adapted to be coupled to a substantially stiff piston part, a second portion integrated with a substantially stiff support member suitable for acoustic sealing purposes, and a flexible member connecting the first and second portions. | 03-17-2011 |
20110299703 | MINIATURE TRANSDUCER ASSEMBLY WITH INTEGRATED DE-COUPLING COILS - The present invention relates to a miniature transducer assembly for a wireless portable terminal. The miniature transducer assembly of the present invention comprises a transducer unit comprising a number of voice coils for displacing a diaphragm of said transducer unit. Moreover, the transducer assembly comprises at least one de-coupling coil for avoiding interference between the transducer unit and an antenna of the wireless portable terminal. In order to reduce the dimensions of the transducer assembly at least one de-coupling coil forms an integral part of a lead-out wire from of a voice coil. | 12-08-2011 |
20120190322 | Customized Audio/Antenna Module And Method For Making The Same - The present invention relates to a method for assembling a self-contained audio/antenna module for a portable communication device, the method comprising the steps of incorporating, into the audio/antenna module, one or more transducers, said incorporation comprising, for at least one transducer, the steps of custom designing and implementing a membrane structure for the at least one transducer in accordance with design constrains provided by an audio/antenna module casing, and incorporating a standard, prefabricated magnetic circuit into the audio/antenna module, said magnetic circuit being adapted to displace the membrane structure of the at least one transducer in accordance with incoming audio drive signals. The invention further relates to an audio/antenna module manufactured according to the above-mentioned method. | 07-26-2012 |
20120314898 | HIGH EFFICIENT MINIATURE ELECTRO-ACOUSTIC TRANSDUCER WITH REDUCED DIMENSIONS - A magnetic circuit includes an inner permanent magnet assembly and an outer permanent magnet assembly, a magnetically permeable yoke, and first and second air gap portions conducting first and second magnetic flux densities, respectively, the first and second air gap portions being adapted to receive first and second voice coil segments, respectively. The magnetic flux density in the first air gap portion is generated by superposition of magnetic flux generated by the inner permanent magnet assembly and magnetic flux generated by the outer permanent magnet assembly, and wherein the magnetic flux density in the second air gap portion is generated substantially exclusively by the inner permanent magnet assembly. | 12-13-2012 |
20140169614 | MINIATURE SUSPENSION MEMBER - The present invention relates to a miniature suspension member for a miniature transducer, said miniature suspension member comprising first and second portions being connected by a flexible member at respective outer regions facing away from a centre of the suspension member, wherein the first portion, the second portion and the flexible member form, in combination, a polymer-based one-piece injection mouldable structure. | 06-19-2014 |
20140360806 | ADHESIVE FREE ATTACHMENT OF TRANSDUCER SUSPENSION MEMBER - The present invention relates to a suspension member for suspending a moveable piston structure of a transducer, the suspension member comprising an attachment region comprising an elastomeric material, wherein at least part of the attachment region is shaped in a manner so as to be able to attach to a fixed portion of the transducer in an adhesive free manner. Moreover, the present invention relates to a suspension member comprising an integrated tolerance compensation means. | 12-11-2014 |